Californian cytokine storm syndrome specialist Humanigen (Nasdaq: HGEN) has executed its first licensing deal in the Asia-Pacific Region, with Telcon RF Pharmaceutical (KQ: 200230) and KPM Tech (KQ: 042040).
Humanigen is developing its lead drug candidate lenzilumab as an option to combat the immune hyper-response - a critical condition characterized by overwhelming systemic inflammation and multiple organ failure.
Lenzilumab is a novel engineered human immunoglobulin monoclonal antibody, with high affinity for human GM-CSF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze